The dual inhibitory profile of EPTIFIBATIDE against both KPC-3 and MSH3, confirmed by multi-method validation, suggests that structural motifs conferring cross-target activity can be prospectively identified by quantum-annealing-based subgraph isomorphism searches in matched carbapenemase and ATPase binding site graphs.

Adversarial Debate Score

65% survival rate under critique

Supporting Research Papers

• Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products

  The Ebola virus (EBOV) is a lethal pathogen causing hemorrhagic fever syndrome which remains a global health challenge. In the EBOV, two multifunctional proteins, VP35 and VP40, have significant roles...

• Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening

  ABSTRACT Ebola virus (EBOV) causes a severe haemorrhagic fever in humans and has a mortality rate over 50%. With no licensed drug treatments available, EBOV poses a significant threat. Investigations ...

• In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40

  VP30 and VP40 proteins of Ebola and Marburg viruses have been recognized as potential targets for antiviral drug development due to their essential roles in the viral lifecycle. Targeting these protei...

• Identification of potential inhibitor against Ebola virus VP35: insight into virtual screening, pharmacoinformatics profiling, and molecular dynamic studies
• The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance.

  Bacteriophage therapy is currently being evaluated as a critical complement to traditional antibiotic treatment. However, the emergence of phage resistance is perceived as a major hurdle to the sustai...

Formal Verification

Source